Cardiff Oncology, Inc.

NASDAQ:CRDF

Biotechnology

Healthcare
$0.84 +2.12%

+$0.03 today

Market cap
$65.27M
Beta
1.38
P/E (TTM)
-1.8
EPS (TTM)
-$0.65
52W Low $1.16High $4.56

Volume 0.86M

Average 1.05M

CRDF Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Cardiff Oncology, Inc.NASDAQ: CRDF

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$9K, compared with $368K a year earlier. Trailing-twelve-month accounts receivables was $214K.

Context

  • Accounts receivables amounted to 99.7% of revenue in FY2025, up 28.8 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$9K or moves back toward the trailing-twelve-month quarterly average of $53.5K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$9K-112.5% QoQ
Last fiscal yearDec 2025
$591K+222.1% YoY
LTMMar 2026
$214K+2045.5% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-102.4%——
1 year+222.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
591K USD
Year-over-year change
+222.1%

Accounts Receivables vs competitors

How CRDF compares with its peers on the latest reported figures

  • Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2045.5% is the 2nd highest of 4, against a peer median of +340.0%.
  • Accounts receivables amounts to 40.8% of revenue for CRDF, versus a peer median of 32.0%.
CRDF Competitors
Accounts Receivables for CRDF and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$2.85M USD+7601.5%+15.2%159.7%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.93M CHF+340.0%-73.6%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$1.01M USD+69.0%—32.0%
CRDFCardiff Oncology, Inc.LTM Mar 2026$214K USD+2045.5%—40.8%
FBRXForte Biosciences, Inc.LTM Mar 2026$0 USD———
PEPGPepGen Inc.LTM Mar 2026$0 USD———
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$0 USD———
ELTXElicio Therapeutics, Inc.LTM Mar 2026$0 USD———
Peer median (excluding CRDF) —+340.0%-29.2%32.0%

Competitors are the stored peer set for CRDF. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(28.29M)(38.7M)(41.44M)(45.43M)(45.85M)
Depreciation & Amortization451K236K398K404K904K
Deferred Income Tax1.32M0000
Stock-Based Compensation3.23M4.26M4.51M4.76M5.69M
Change in Working Capital(1.79M)(380K)6.57M3.17M2.18M
Accounts Receivables(215K)(236K)483K(484K)591K
Inventory00000
Accounts Payables719K1.35M2.83M2.99M2.2M
Other Working Capital(2.29M)(1.49M)3.25M671K(614K)
Other Non-Cash Items2.03M772K(921K)(598K)(848K)
Operating Cash Flow(23.04M)(33.82M)(30.89M)(37.69M)(37.92M)
Capital Expenditures(205K)(892K)(582K)(80K)(44K)
Acquisitions (Net)205K(114K)000
Purchases of Investments(174.39M)(91.23M)(70.08M)(23.56M)(71.12M)
Sales of Investments43.14M130.27M106.86M37.37M73.25M
Other Investing Activities(205K)114K00(744K)
Investing Cash Flow(131.45M)38.15M36.2M13.73M1.34M
Debt Repayment00000
Common Stock Issued34.19M75K053.41M2.58M
Common Stock Repurchased00000
Dividends Paid(24K)(414K)000
Other Financing Activities1.29M414K0373K0
Financing Cash Flow35.45M75K053.78M2.58M
Effect of Forex Changes00000
Net Change in Cash(119.04M)4.4M5.31M29.82M(34M)
Free Cash Flow(23.25M)(34.71M)(31.47M)(37.77M)(37.97M)

Cardiff Oncology, Inc.

NASDAQ:CRDF

Intrinsic Alpha fair value

Locked

Current Price

$0.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.